{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_relationships_comments in Relationship Comments (approximate match)
Status:
US Previously Marketed
Source:
EXBLIFEP by ALLECRA THERAPS
(2024)
Source URL:
First approved in 2024
Source:
EXBLIFEP by ALLECRA THERAPS
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
M017
(2025)
Source URL:
First approved in 2025
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Paeonol (2-hydroxy-4-methoxyacetophenone) is a major phenolic component of the dried root bark of Paeonia suffruticosa Andrews (Paeoniaceae). Paeonol exhibits a wide variety of bioactivities including anti-inflammatory, antioxidative, immunoregulatory, antihypertensive, anti-hyperglycemic, antibacterial, anti-thrombotic, and antitumor effects. Paeonol inhibits anaphylactic reaction by regulating histamine and TNF-α. Paeonol tablets have been used for the treatment of rheumatic arthritis, fever, headache and neuralgia in Chinese clinics.
Status:
Possibly Marketed Outside US
Source:
Zankiren hydrochloride by Abbott
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zankiren (A-72517) is a peptidomimetic renin inhibitor with high potency and specificity. The drug was shown to reduce blood pressure in healthy volunteers after oral administration. In another clinical trial, zankiren exerted a renal vasodilator action. Despite positive results from initial clinical trials, further development of zankiren was discontinued.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
US Approved OTC
Source:
21 CFR 333.110(a) first aid antibiotic:ointment bacitracin
Source URL:
First marketed in 1921
Class:
MIXTURE
Targets:
Conditions:
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188887: Phase 3 Interventional Completed IgA Nephropathy
(2018)
Source URL:
Class:
PROTEIN